

- in Fabry's disease: ceramidetrihexosidase deficiency. *N. Engl. J. Med.* **276**, 1163–1167
- Desnick, R.J., Ioannou, Y.A., and Eng, C.M. (2001) in *The Metabolic and Molecular Bases of Inherited Disease* (Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D., eds.), pp. 3733–3774, McGraw-Hill, New York
  - Ishii, S., Kase, R., Sakuraba, H., and Suzuki, Y. (1993) Characterization of a mutant  $\alpha$ -galactosidase gene product for the late-onset cardiac form of Fabry disease. *Biochem. Biophys. Res. Comm.* **197**, 1585–1589
  - Ishii, S., Chang, H.-H., Kawasaki, K., Yasuda, K., Wu, H.-L., Garman, S.C., and Fan, J.-Q. (2007) Mutant  $\alpha$ -galactosidase A enzymes identified in Fabry patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. *Biochem. J.* **406**, 285–295
  - Hamanaka, R., Shinohara, T., Yano, S., Nakamura, M., Yasuda, A., Yokoyama, S., Fan, J.-Q., Kawasaki, K., Watanabe, M., and Ishii, S. (2008) Rescue of mutant  $\alpha$ -galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes. *Biochim. Biophys. Acta* **1782**, 408–413
  - Fan, J.-Q., Ishii, S., Asano, N., and Suzuki, Y. (1999) Accelerated transport and maturation of lysosomal  $\alpha$ -galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. *Nat. Med.* **5**, 112–115
  - Fan, J.-Q. and Ishii, S. (2003) Cell-based screening of active site specific chaperone for the treatment of Fabry disease. *Methods Enzymol.* **363**, 412–420
  - Fan, J.-Q. and Ishii, S. (2007) Active-site-specific chaperone therapy for Fabry disease: Yin and Yang of enzyme inhibitors. *FEBS J.* **274**, 4962–4971
  - Benjamin, E.R., Flanagan, J.J., Schilling, A., Chang, H.H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R.J., Lockhart, D.J., and Valenzano, K.J. (2009) The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. *J. Inherit. Metab. Dis.* **32**, 424–440
  - Ohshima, T., Murray, G.J., Swaim, W.D., Longenecker, G., Quirk, J.M., Cardarelli, C.O., Sugimoto, Y., Pastan, I., Gottesman, M.M., Brady, R.O., and Kulkarni, A.B. (1997)  $\alpha$ -Galactosidase A deficient mice: a model of Fabry disease. *Proc. Natl Acad. Sci. USA* **94**, 2540–2544
  - Ioannou, Y.A., Zeidner, K.M., Gordon, R.E., and Desnick, R.J. (2001) Fabry disease: preclinical studies demonstrate the effectiveness of  $\alpha$ -galactosidase A replacement in enzyme-deficient mice. *Am. J. Hum. Genet.* **68**, 14–25
  - Ziegler, R.J., Yew, N.S., Li, C., Cherry, M., Berthlette, P., Romanczuk, H., Ioannou, Y.A., Zeidner, K.M., Desnick, R.J., and Cheng, S.H. (1999) Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. *Hum. Gene Ther.* **10**, 1667–1682
  - Takenaka, T., Murray, G.J., Qin, G., Quirk, J.M., Ohshima, T., Qasba, P., Clark, K., Kurkarni, A.B., Brady, R.O., and Medin, J.A. (2000) Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. *Proc. Natl Acad. Sci. USA* **97**, 7515–7520
  - Nakamura, G., Maruyama, H., Ishii, S., Shimotori, M., Kameda, S., Kono, T., Miyazaki, J., Kulkarni, A.B., and Gejyo, F. (2008) Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice. *Mol. Biotechnol.* **38**, 109–119
  - Abe, A., Gregoory, S., Lee, L., Killen, P.D., Brady, R.O., Kulkarni, A., and Shayman, J.A. (2000) Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. *J. Clin. Invest.* **105**, 1563–1571
  - Ishii, S., Yoshioka, H., Mannen, K., Kulkarni, A.B., and Fan, J.-Q. (2004) Transgenic mouse expressing human mutant  $\alpha$ -galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. *Biochim. Biophys. Acta* **1690**, 250–257
  - Shimmoto, M., Kase, R., Itoh, K., Utsumi, K., Ishii, S., Taya, C., Yonekawa, H., and Sakuraba, H. (1997) Generation and characterization of transgenic mice expressing a human mutant  $\alpha$ -galactosidase with an R301Q substitution causing a variant form of Fabry disease. *FEBS Lett.* **417**, 89–91
  - Ishii, S., Chang, H.-H., Yoshioka, H., Shimada, T., Mannen, K., Higuchi, Y., Taguchi, A., and Fan, J.-Q. (2009) Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. *J. Pharmacol. Exp. Ther.* **328**, 723–731
  - Kojima, Y., Fukumoto, S., Furukawa, K., Okajima, T., Wiels, J., Yokoyama, K., Suzuki, Y., Urano, T., Ohta, M., and Furukawa, K. (2000) Molecular cloning of globotriaosylceramide/CD77 synthase, a glycosyltransferase that initiates the synthesis of globo series glycosphingolipids. *J. Biol. Chem.* **275**, 15152–15156
  - Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* **108**, 193–200
  - Matsuda, J., Suzuki, O., Oshima, A., Yamamoto, Y., Noguchi, A., Takimoto, K., Itoh, M., Matsuzaki, Y., Yasuda, Y., Ogawa, S., Sakata, Y., Nanba, E., Higaki, K., Ogawa, Y., Tominaga, L., Ohno, K., Iwasaki, H., Watanabe, H., Brady, R.O., and Suzuki, Y. (2003) Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. *Proc. Natl Acad. Sci. USA* **100**, 15912–15917
  - Ishii, S., Katsumura, T., Shiozuka, C., Ooyauchi, K., Kawasaki, K., Takigawa, S., Fukushima, T., Tokuji, Y., Kinoshita, M., Ohnishi, M., Kawahara, M., and Ohba, K. (2008) Anti-inflammatory effect of buckwheat sprout in lipopolysaccharide-activated human colon cancer cells and mice. *Biosci. Biotechnol. Biochem.* **72**, 3148–3157
  - Shin, I.-S., Nishikawa, K., Maruyama, H., and Ishii, S. (2006) Histidine-tagged Shiga toxin B subunit binding assay: simple and specific determination of Gb3 content in mammalian cells. *Chem. Pharm. Bull.* **54**, 522–527
  - Yano, S., Kashima, K., Daa, T., Urabe, S., Tsuji, K., Nakayama, I., and Yokoyama, S. (2003) An antigen retrieval method using an alkaline solution allows immunoelectron microscopic identification of secretory granules in conventional epoxy-embedded tissue sections. *J. Histochem. Cytochem.* **51**, 199–204
  - Jacewicz, M., Clausen, H., Nudelman, E., Donohue-Rolfe, A., and Keusch, G.T. (1986) Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. *J. Exp. Med.* **163**, 1391–1404
  - Lingwood, C.A., Law, H., Richardson, S., Petric, M., Brunton, J.L., De Grandis, S., and Karmali, M. (1987) Glycolipid binding of purified and recombinant *Escherichia coli* produced verotoxin *in vitro*. *J. Biol. Chem.* **262**, 8834–8839

C. Shiozuka *et al.*

27. McCluer, R.H. and Gross, S.K. (1985) Biosynthesis of neutral glycosphingolipids in kidney slices from male and female mice. *J. Lipid Res.* **26**, 593–599
28. Ohshima, T., Schiffmann, R., Murray, G.J., Kopp, J., Quirk, J.M., Stahl, S., Chan, C.C., Zerfas, P., Tao-Cheng, J.H., Ward, J.M., Brady, R.O., and Kulkarni, A.B. (1999) Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. *Proc. Natl Acad. Sci. USA* **96**, 6423–6427
29. Khanna, R., Soska, R., Lun, Y., Feng, J., Franscella, M., Young, B., Brignol, N., Pellegrino, L., Sitaraman, S., Desnick, R.J., Benjamin, E.R., Lockhart, D.J., and Valenzano, K.J. (2010) The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. *Mol. Ther.* **18**, 23–33
30. Asano, N., Ishii, S., Kizu, H., Ikeda, K., Yasuda, K., Kato, A., Martin, O.R., and Fan, J.-Q. (2000) *In vitro* inhibition and intracellular enhancement of lysosomal  $\alpha$ -galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. *Eur. J. Biochem.* **267**, 4179–4186

